President, CEO, and Cofounder of Actym Therapeutics, Inc.
Christopher Thanos is an inventor of Actym’s core technology, has 18 of years of biotechnology industry experience. Previously, he was appointed Head of Biotherapeutics Discovery at Halozyme (NASDAQ: HALO), leading Immunology, Cell Biology, Protein Engineering and Production efforts to populate HALO’s oncology pipeline. Dr. Thanos is the lead inventor of PEG-ADA2 (US Patent 9,969,998), a checkpoint inhibitor that targets immuno-suppressive adenosine, currently in candidate nomination studies. Translational I/O studies from Dr. Thanos’ group on HALO’s PEG-PH20® therapeutic candidate (Phase III, pancreatic cancer) led to a broad strategic alliance between Halozyme and Genentech to study a combination between Tecentriq® (anti-PDL1) and PEG-PH20® in the clinic across 8 solid tumor types. Dr. Thanos’ group also developed an IDE-approved companion diagnostic currently being used in a global phase 3 pancreatic cancer trial. Before HALO, Dr. Thanos was Head of Protein Engineering at Sutro Biopharma (Nasdaq:STRO). Dr. Thanos is a named inventor on nine issued US patents assigned to Sutro, and is the lead inventor of core platform technology used by both Sutro Biopharma and SutroVax Inc. (US Patent 9,650,621). Prior to that, Dr. Thanos co-founded Catalyst Biosciences (NASDAQ:CBIO), where he participated in raising venture capital, and helped to establish the company’s technology platform. He is a co-inventor of Factor VIIa marzeptacog alfa, currently in Phase II/III clinical trials (purchased by Wyeth/Pfizer, garnering $41.2 million in milestones), Factor IX CB2679d/ISU304, currently in Phase I/II trials, and Factor Xa, currently in pre-clinical development. Dr. Thanos also devoted significant effort to establishing Catalyst’s directed evolution-based, protein engineering platform. Earlier in his career, Dr. Thanos was a National Cancer Institute Postdoctoral Fellow under Professor Jim Wells at UCSF and Sunesis (NASDAQ:SNSS). He earned a Ph.D. in Molecular Biology and Biochemistry from UCLA where he was an NIH Chemistry / Biology Interface Predoctoral Fellow. At UCLA, Dr. Thanos discovered the atomic structure and binding mode of SAM domains- one of the most common protein modules found in eukaryotic cells, work which was prominently featured in Science Magazine. He is a named inventor on 17 issued and multiple pending patent applications in the area of biological and cellular therapeutics and a first author of several peer-reviewed articles in top tier journals. As a recognized thought leader in the field, Dr. Thanos is frequently called upon to present as an invited speaker, workshop leader, and conference chairman at international scientific conferences focused on biological therapeutics to treat cancer.
Follow Christopher Thanos:
About Actym Therapeutics, Inc.: Actym Therapeutics is a privately-held biotech focused on the discovery and development of novel immuno-oncology therapies to treat cancer.